赛升药业: 2025年半年度报告摘要

Core Viewpoint - The company reported a decrease in operating revenue and a significant increase in net profit attributable to shareholders in the first half of 2025 compared to the same period last year [1][2]. Financial Performance - Operating revenue for the reporting period was CNY 196,801,173.60, a decrease of 8.40% from CNY 214,836,918.78 in the previous year [1]. - Net profit attributable to shareholders was CNY 47,786,232.79, an increase of 145.45% compared to a loss of CNY 105,150,328.07 in the same period last year [1]. - Net profit after deducting non-recurring gains and losses was not specified in the provided data [1]. - Net cash flow from operating activities was CNY 29,341,900.02, down 58.28% from CNY 70,325,566.70 in the previous year [1]. - Basic earnings per share were CNY 0.10, up 145.45% from a loss of CNY 0.22 [1]. - Diluted earnings per share were also CNY 0.10, reflecting the same percentage increase [1]. - The weighted average return on net assets was 1.41%, an increase of 4.52% compared to -3.11% in the previous year [1]. Asset and Equity Position - Total assets at the end of the reporting period were CNY 3,598,239,362.25, an increase of 1.31% from CNY 3,551,848,565.47 at the end of the previous year [2]. - Net assets attributable to shareholders were CNY 3,404,744,733.61, up 1.42% from CNY 3,357,111,952.59 [2]. Shareholder Information - The largest shareholder, Ma Qiao, holds 49.51% of the shares, totaling 238,464,000 shares [2]. - Other significant shareholders include Ma Li with 6.20% and Liu Shuqin with 1.82% [2]. - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period [4].